News
The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...
Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...
1don MSN
A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...
Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...
USA: Researchers have found in a new study that patients with idiopathic intracranial hypertension (IIH) treated with ...
People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new ...
GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...
Initially developed to treat type-2 diabetes, the drugs have more recently demonstrated a capacity to neutralize patients' ...
Glucagon-like peptide 1 receptor agonist (GLP-1 RA) therapy in idiopathic intracranial hypertension is associated with significant reductions in medication use, symptoms/signs, and procedural ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
2d
Verywell Health on MSN4 Medications That May Interact With CoQ10CoQ10 may interact with certain medications, causing side effects or making them less effective. Find out if you shouldn't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results